Skip to main content
Advertising

Originally published April 23, 2012 at 4:45 AM | Page modified April 23, 2012 at 7:02 AM

  • Share:
             
  • Comments (0)
  • Print

AstraZeneca buying Ardea in $1.26 bln deal

Anglo-Swedish drug company AstraZeneca PLC is buying Ardea Biosciences, Inc., in a deal which values the U.S. biotech company at $1.26 billion.

The Associated Press

Most Popular Comments
Hide / Show comments
No comments have been posted to this article.
Start the conversation >

advertising

LONDON —

Anglo-Swedish drug company AstraZeneca PLC is buying Ardea Biosciences, Inc., in a deal which values the U.S. biotech company at $1.26 billion.

AstraZeneca said Monday that it had agreed the takeover with San Diego-based Ardea, which is developing a treatment for elevated blood levels of uric acid in patients with gout.

AstraZeneca is paying $32 per share, representing a 54 percent premium on the closing share price last Friday.

The boards of both companies have approved the deal, and AstraZeneca says it has secured commitments from 30 percent of Ardea shareholders.

AstraZeneca says the deal is expected to close by the end of September.

News where, when and how you want it

Email Icon


Advertising